The first domestic biosimilar drug of smeglutide started clinically from Jiuyuan Gene

On November 30th, according to the Insight database, Jiuyuan Gene's smeglutide biosimilar was started clinically, which was the first in China

From: Insight database (http://db.

Since June this year, domestic pharmaceutical companies have successively started to declare biosimilars of smeglutide, and there are currently three

Current research and development progress of domestic smeglutide biosimilar drugs

From: Insight Project Library (http://db.

Smeglutide is the well-deserved king in the field of GLP-1

From: Armstrong

In order to capture the hypoglycemic drug market, Eli Lilly’s next-generation GLP-1/GIPR dual target agonist Tirzepatide has completed 5 phase III SURPASS series of clinical head-to-head Megglutide successfully, and submitted a marketing application to the FDA with priority review coupons , It is expected that this potential blockbuster will be introduced to the market in the first half of 2022 through an accelerated approach

There is never a lack of competition in the field of hypoglycemic drugs